Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | HTR7 | P34969 | 2/20 | 0.39 |
| ▸ | HTR6 | P50406 | 12/20 | 0.38 |
| ▸ | CCR5 | P51681 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2957622 | 0.87 | HTR2A (0.42) | HTR2AHTR1ADRD2HTR7HTR6 | |
| SCHEMBL13240503 | 0.85 | HTR2A (0.39) | HTR2AHTR1ADRD2HTR7HTR6 | |
| SCHEMBL14200033 | 0.84 | KCNH2 (0.40) | HTR2AHTR1ADRD2HTR7HTR6 | |
| SCHEMBL2952107 | 0.79 | HTR6 (0.40) | HTR2AHTR1ADRD2HTR7HTR6 | |
| SCHEMBL2952104 | 0.78 | HTR6 (0.47) | HTR2ADRD2HTR7HTR6KCNH2 | |
| Hydrochloric Acid SCHEMBL2963663 | 0.78 | HTR6 (0.46) | HTR2ADRD2HTR7HTR6KCNH2 | |
| SCHEMBL2963683 | 0.74 | HTR6 (0.49) | HTR6 | |
| SCHEMBL2953919 | 0.72 | HTR6 (0.44) | HTR6 | |
| SCHEMBL2953515 | 0.71 | HTR6 (0.48) | HTR6 | |
| SCHEMBL2962731 | 0.70 | HTR6 (0.48) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759389-B2 | Chroman derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-07-20 | — | — | US | disclosed |
| EP-1831191-B1 | CHROMAN DERIVATIVES AND THEIR USE AS 5-HT RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2008-05-21 | — | — | EP | disclosed |
| EP-1831191-A1 | CHROMAN DERIVATIVES AND THEIR USE AS 5-HT RECEPTOR LIGANDS | F. Hoffmann-Roche AG (CH) | 2007-09-12 | — | — | EP | disclosed |
| US-20060148888-A1 | Chroman derivatives and uses thereof | ROCHE PALO ALTO LLC | 2006-07-06 | — | — | US | disclosed |
| WO-2006066746-A1 | CHROMAN DERIVATIVES AND THEIR USE AS 5-HT RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148888-A1 | Chroman derivatives and uses thereof | RB1, RECQL, CCNY | HTR2A 169/4885HTR1A 123/4885DRD2 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.